Read an analysis on Harrow's Q3 earnings, inventory issues and strategic pivots, with a focus on VEVYE and IHEEZO's potential for recovery in Q4.

United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. Check out why I rate UTHR ...